Prophylaxis Against Invasive Fungal Disease for Neutropenic Children and Young Adults

Dylan W. De Lange; Roger J.M. Brüggemann

doi:10.1001/jama.2020.0172

Prophylaxis Against Invasive Fungal Disease for Neutropenic Children and Young Adults

Dylan W. De Lange, Roger J.M. Brüggemann

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	997-998
Number of pages	2
Journal	JAMA
Volume	323
Issue number	10
DOIs	https://doi.org/10.1001/jama.2020.0172
Publication status	Published - 10 Mar 2020
Externally published	Yes

Access to Document

10.1001/jama.2020.0172

Cite this

@article{e16dbea1e04b4f89b1c69e5ac97d3b6f,

title = "Prophylaxis Against Invasive Fungal Disease for Neutropenic Children and Young Adults",

author = "{De Lange}, {Dylan W.} and Br{\"u}ggemann, {Roger J.M.}",

note = "Funding Information: Author Affiliations: Division of Infectious Diseases, The Children{\textquoteright}s Hospital of Philadelphia, Philadelphia, Pennsylvania (Fisher); Division of Haematology Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada (Sung). Corresponding Author: Brian T. Fisher, DO, MSCE, MPH, Department of Pediatrics, The Roberts Center for Pediatric Research, The Children{\textquoteright}s Hospital of Philadelphia, 2716 South St, Room 10362, Philadelphia, PA 19146 ([email protected]). Conflict of Interest Disclosures: Dr Fisher reported that his institution receives funding from Merck, Pfizer, and the Children{\textquoteright}s Oncology Group for research studies. He also serves on a data and safety monitoring board for Astellas. Dr Sung reported receiving grants and salary support from the Children{\textquoteright}s Oncology Group. 1. Fisher BT, Zaoutis T, Dvorak CC, et al. Effect of caspofungin vs fluconazole prophylaxis on invasive fungal disease among children and young adults with acute myeloid leukemia: a randomized clinical trial. JAMA. 2019;322(17):1673-1681. doi:10.1001/jama.2019.15702 2. Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. Twenty years of the SENTRY Antifungal Surveillance Program: results for Candida species from 1997-2016. Open Forum Infect Dis. 2019;6(suppl 1):S79-S94. doi:10.1093/ ofid/ofy358 3. Blyth CC, Chen SCA, Slavin MA, et al; Australian Candidemia Study. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics. 2009;123 (5):1360-1368. doi:10.1542/peds.2008-2055 4. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol. 2010;48(7):2373-2380. doi:10.1128/JCM.02390-09 5. Science M, Robinson PD, MacDonald T, Rassekh SR, Dupuis LL, Sung L. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2014;61 (3):393-400. doi:10.1002/pbc.24847 6. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50. doi:10.1093/cid/civ1194 Funding Information: Funding/Support: Funding was provided by Myriad Genetics, by the Suzanne Pride Bryan Fund for Breast Cancer Research, the Jan Weimer Faculty Chair in Breast Oncology, and the BRCA Foundation. The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, and the US Department of Health and Human Services (HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C).",

year = "2020",

month = mar,

day = "10",

doi = "10.1001/jama.2020.0172",

language = "English",

volume = "323",

pages = "997--998",

journal = "JAMA",

issn = "0098-7484",

publisher = "American Medical Association",

number = "10",

}

TY - JOUR

T1 - Prophylaxis Against Invasive Fungal Disease for Neutropenic Children and Young Adults

AU - De Lange, Dylan W.

AU - Brüggemann, Roger J.M.

N1 - Funding Information: Author Affiliations: Division of Infectious Diseases, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania (Fisher); Division of Haematology Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada (Sung). Corresponding Author: Brian T. Fisher, DO, MSCE, MPH, Department of Pediatrics, The Roberts Center for Pediatric Research, The Children’s Hospital of Philadelphia, 2716 South St, Room 10362, Philadelphia, PA 19146 ([email protected]). Conflict of Interest Disclosures: Dr Fisher reported that his institution receives funding from Merck, Pfizer, and the Children’s Oncology Group for research studies. He also serves on a data and safety monitoring board for Astellas. Dr Sung reported receiving grants and salary support from the Children’s Oncology Group. 1. Fisher BT, Zaoutis T, Dvorak CC, et al. Effect of caspofungin vs fluconazole prophylaxis on invasive fungal disease among children and young adults with acute myeloid leukemia: a randomized clinical trial. JAMA. 2019;322(17):1673-1681. doi:10.1001/jama.2019.15702 2. Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. Twenty years of the SENTRY Antifungal Surveillance Program: results for Candida species from 1997-2016. Open Forum Infect Dis. 2019;6(suppl 1):S79-S94. doi:10.1093/ ofid/ofy358 3. Blyth CC, Chen SCA, Slavin MA, et al; Australian Candidemia Study. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics. 2009;123 (5):1360-1368. doi:10.1542/peds.2008-2055 4. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol. 2010;48(7):2373-2380. doi:10.1128/JCM.02390-09 5. Science M, Robinson PD, MacDonald T, Rassekh SR, Dupuis LL, Sung L. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2014;61 (3):393-400. doi:10.1002/pbc.24847 6. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50. doi:10.1093/cid/civ1194 Funding Information: Funding/Support: Funding was provided by Myriad Genetics, by the Suzanne Pride Bryan Fund for Breast Cancer Research, the Jan Weimer Faculty Chair in Breast Oncology, and the BRCA Foundation. The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, and the US Department of Health and Human Services (HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C).

PY - 2020/3/10

Y1 - 2020/3/10

UR - http://www.scopus.com/inward/record.url?scp=85081537842&partnerID=8YFLogxK

U2 - 10.1001/jama.2020.0172

DO - 10.1001/jama.2020.0172

M3 - Letter

C2 - 32154852

AN - SCOPUS:85081537842

SN - 0098-7484

VL - 323

SP - 997

EP - 998

JO - JAMA

JF - JAMA

IS - 10

ER -